Principle: distinguish standard oncology from complementary approaches
Surgery, radiotherapy, chemotherapy, hormone therapy, targeted agents and approved immunotherapies have different roles depending on tumour type and stage. Complementary approaches should not generally replace these established treatment pathways.
Surgery
If a tumour can be completely or partially removed surgically, surgery may play a central role. For immunological approaches, the timing in relation to surgery, woand healing and recovery must be considered.
Chemotherapy
Chemotherapys can reduce tumour burden but also affect blood counts and immune-cell populations. For complementary DCT, coordination with blood collection, cell manufacturing and administrations is therefore important.
Radiotherapy
Radiotherapy can be highly effective locally and can also trigger immunological effects. Timing, irradiated volume, blood count and general condition must be considered in combinations.
Checkpoint Inhibitors
Checkpoint inhibitors release inhibitory signals in the immune system and are approved for certain tumour types and situations. Biomarkers, previous therapies, autoimmune risks and potential immune-mediated adverse effects are relevant.
Targeted Therapys
Molecular alterations such as certain driver mutations may enable the use of targeted medicines. This molecular information is part of personalised treatment planning.
Hormone Therapy
In hormone-dependent tumours, particularly certain breast and prostate cancers, hormonal therapies can play a central long-term role. Complementary immunological approaches must be integrated into this overall plan.
Terapia con células dendríticas
Dendritic-cell approaches aim to process patient-specific tumour antigens for a more targeted T-cell response. The scientific evidence is tumour-specific and heterogeneous and must not be equated with a guaranteed individual effect.
Immunological and supportive context
Blood count, immune status, inflammatory parameters, nutritional status, concomitant medication, infections and physical resilience may be relevant for planning. Supportive measures are intended to reduce burden and support established oncological treatment.
Timing: why the sequence matters
| Treatment | What may be relevant for coordination |
|---|---|
| Surgery | Woand healing, general condition, pathology, tumour material |
| Chemotherapy | Blood count, immune-cell counts, cycle timing, infection risk |
| Radiotherapy | Irradiated volume, blood count, recovery phase |
| Checkpoint Inhibitors | Immune toxicity, concomitant medication, steroids, autoimmune risk |
| DZT | Blood collection, manufacturing, transport, administration, follow-up monitoring |
Follow-up Monitoring
Assessment is not based on a single parameter. Clinical condition, imaging, blood values, immune status and – where used – standardized tumour-dynamics or CTC trends are considered together.